Free Trial
NASDAQ:ACER

Acer Therapeutics (ACER) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.66
$0.85
50-Day Range
$0.66
$0.90
52-Week Range
$0.55
$4.56
Volume
574,600 shs
Average Volume
N/A
Market Capitalization
$16.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.50
ACER stock logo

About Acer Therapeutics Stock (NASDAQ:ACER)

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.

ACER Stock News Headlines

Anumana Appoints Harry S. Palmin as CFO
North Avenue closure
Relief Therapeutics Holding SA RLF
Acer Therapeutics Inc. (ACER)
HC Wainwright Downgrades Acer Therapeutics
Roth MKM Downgrades Acer Therapeutics
See More Headlines
Receive ACER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acer Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/19/2021
Today
5/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ACER
Employees
30
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$1.50
High Stock Price Target
$1.50
Low Stock Price Target
$1.50
Potential Upside/Downside
+127.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-26,240,000.00
Pretax Margin
-13,034.14%

Debt

Sales & Book Value

Annual Sales
$1.26 million
Book Value
($1.05) per share

Miscellaneous

Free Float
19,522,000
Market Cap
$16.15 million
Optionable
Not Optionable
Beta
0.23

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Christopher Schelling (Age 47)
    Founder, President, CEO & Director
    Comp: $739.82k
  • Mr. Harry S. Palmin (Age 53)
    Chief Financial Officer
    Comp: $545.36k
  • Dr. Adrian Quartel FFPM (Age 56)
    M.D., Chief Medical Officer
    Comp: $421.65k
  • Ms. Tanya Hayden (Age 43)
    Chief Operating Officer
  • Mr. John Michael Klopp (Age 48)
    Chief Technical Officer
  • Mr. Donald R. Joseph J.D. (Age 69)
    Chief Legal Officer & Secretary
    Comp: $490.28k
  • Mr. Bernie Paul (Age 64)
    Chief People Officer
  • Mr. Jefferson E. Davis (Age 56)
    Chief Business Officer
    Comp: $326.67k
  • Mr. Jason Kneeland CPA
    VP of Finance & Controller

ACER Stock Analysis - Frequently Asked Questions

Should I buy or sell Acer Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ACER shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACER, but not buy additional shares or sell existing shares.
View ACER analyst ratings
or view top-rated stocks.

What is Acer Therapeutics' stock price target for 2024?

3 Wall Street analysts have issued twelve-month price objectives for Acer Therapeutics' shares. Their ACER share price targets range from $1.50 to $1.50. On average, they anticipate the company's share price to reach $1.50 in the next twelve months. This suggests a possible upside of 127.2% from the stock's current price.
View analysts price targets for ACER
or view top-rated stocks among Wall Street analysts.

How were Acer Therapeutics' earnings last quarter?

Acer Therapeutics Inc. (NASDAQ:ACER) announced its quarterly earnings data on Friday, November, 19th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05.

What is Jason Chen's approval rating as Acer Therapeutics' CEO?

64 employees have rated Acer Therapeutics Chief Executive Officer Jason Chen on Glassdoor.com. Jason Chen has an approval rating of 99% among the company's employees. This puts Jason Chen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Acer Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), Amarin (AMRN), VBI Vaccines (VBIV), NVIDIA (NVDA), Idera Pharmaceuticals (IDRA) and Inovio Pharmaceuticals (INO).

Does Acer Therapeutics have any subsidiaries?
The following companies are subsidiares of Acer Therapeutics: Opexa Therapeutics Inc..
Read More
This page (NASDAQ:ACER) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners